Sagimet Biosciences Inc. SGMT
Set alert
9.93 USD +0.24 +2.50%
As of Nov 3, 12:56 PM ET
9.66 Day range 10.16
4.55 52-week range 11.17
- YTD
- +67.78%
- 1 year
- +23.23%
- Open
- 9.80
- Prev close
- 9.69
- Mkt cap
- 704.48M
- Vol
- 207.72K
- Avg vol
- 1.32M
- EPS
- -1.27
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 9.66
- High
- 10.16
- Forward P/E
- -1.40
- Beta
- 0.00
- Short ratio
- 1.37
- Inst. own
- 66.94%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 5.28
- 200-d avg
- 4.27
- 1y target
- 29.14
Analyst view
Price target (mean) 29.14 +193.4% upside
Now 9.93
- Target (low)
- 6.00
- Target (mean)
- 29.14
- Target (high)
- 67.00
Ratings (0m) 8 7 buy · 1 hold · 0 sell
- Strong buy3
- Buy4
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 8
- 1 month ago 7
- 2 months ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.632 | -0.82 – -0.54 | 0.00 | 0.0% | 0 | 0.0% | 5 |
| Next quarter | -0.71674 | -1.08 – -0.34372 | -0.23 | -211.6% | 0 | 0.0% | 5 |
| Current year | -1.58 | -1.78 – -1.47 | -2.66 | +40.5% | 0 | -100.0% | 6 |
| Next year | -3.55 | -4.99 – -1.29 | -1.58 | -124.2% | 1.43M | 0.0% | 7 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 6, 2024 | Oppenheimer | Initiated | — | Outperform |
| Nov 15, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 12, 2024 | UBS | Initiated | — | Buy |
| Oct 31, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 2, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 15, 2024 | JMP Securities | Maintained | Market Outperform | Market Outperform |
| Aug 15, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jul 1, 2024 | Goldman Sachs | Maintained | Neutral | Neutral |
| Jun 14, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 7, 2024 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Jun 7, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 24, 2024 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| May 24, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 16, 2024 | Goldman Sachs | Maintained | Buy | Buy |
| May 16, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 2, 2024 | HC Wainwright & Co. | Initiated | — | Buy |
| Mar 26, 2024 | Goldman Sachs | Maintained | Buy | Buy |
| Mar 25, 2024 | Leerink Partners | Initiated | — | Outperform |
| Feb 7, 2024 | JMP Securities | Maintained | Market Outperform | Market Outperform |
| Jan 23, 2024 | Goldman Sachs | Maintained | Buy | Buy |
| Jan 23, 2024 | JMP Securities | Maintained | Market Outperform | Market Outperform |
| Jan 22, 2024 | JMP Securities | Maintained | Market Outperform | Market Outperform |
| Dec 5, 2023 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Aug 8, 2023 | TD Cowen | Initiated | — | Outperform |
| Aug 8, 2023 | Piper Sandler | Initiated | — | Overweight |
| Aug 8, 2023 | JMP Securities | Initiated | — | Market Outperform |
| Aug 8, 2023 | Goldman Sachs | Initiated | — | Buy |